While many genetic factors that increase the risk of multiple sclerosis (MS) are shared across ancestral backgrounds, a study identified a variant that may reduce MS risk in South Asian people, which had not been seen in European studies — suggesting that studies focusing mainly on people of European descent…
Immunic Therapeutics has been granted a new patent in Europe covering multiple dosing regimens of its experimental therapy vidofludimus calcium and related molecules for multiple sclerosis (MS) and other indications. The patent, titled “Dosage Regimen of Vidofludimus for Use in the Treatment of a Chronic Inflammatory…
Discussion
In the not-too-distant past, when my hands were still deft enough to use tools, I really enjoyed working on vehicles. The fact that they weren’t vehicles I depended on every day helped make it a hobby I enjoyed, rather than a chore. Like any hobby, it had its dull moments,…
Loss of brain volume (brain atrophy), a measure often used in clinical trials to track disease progression, may not accurately reflect worsening disability in people with primary progressive multiple sclerosis (PPMS). That’s according to a new analysis of data from the Phase 3 PROMISE trial, in which measures of…
Although the total number of people living with multiple sclerosis (MS) has increased globally in recent decades due to population growth and aging, MS is causing fewer deaths and less disability now than in the past, according to a new study. Predictions also suggest that this trend toward reduced…
Get regular updates to your inbox.
